Modulating the function of TNF-α and IL-1β has remarkable effects on evolution of the infarct in both experimental and human stroke at the early phase of stroke, corresponding to the therapeutic window (<4.5 h) [4, 62, 63]. This evidence concerns the gene IL1B and stroke disorder.